Good MorningEquity markets were relatively unchanged on Thursday as traders digested the previous day's news. The shift in FOMC policy is promising but may not be the great news equity markets seek. While the Fed has signaled the peak of interest rates and oncoming cuts, the news is already spurring demand for homes and energy, raising the possibility inflation will accelerate again. The rate on the 10-year treasury fell to the lowest level since July during the session, indicating a significant decline in mortgage rates, while the price of oil surged more than 3.5% at the session's peak on demand hope.
The S&P 500 is still in rally mode and will likely end the year higher than it is now. The caution for traders is that the index remains below the all-time high and may be unable to cross the threshold to a new all-time high without another catalyst to drive it. The next significant catalyst is the PCE price index due on December 22nd, just in time to usher in the Santa Claus Rally if it confirms cooling inflation. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Consumer Discretionary | |
Ford Motor Co. (NYSE: F) just threw a wrench into the machinery of automotive stocks, when it comes to EV manufacturing.
Anytime you’re driving around, noticing the cars on the road, it’s easy to make two observations about EV adoption.
First, it’s growing. There are more EVs ... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Consumer Discretionary | |
The reality is that nothing lasts forever, including your home and everything in it. Just when you think all is quiet on the home repair front, your water heater will go out. Or your kids will throw a baseball through the living room window. Or an episode of Fixer Upper will spark a desire to rede... Read the Full Story |
|
Markets | |
If the financial markets were an orchestra, consumer discretionary would be the melody — it's not always the most dominant tune. Still, its fluctuations and rhythms often guide the mood and tempo of the overall market performance. From luxury goods to leisurely pursuits, consumer discretiona... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Technology | |
Jabil, Inc. (NASDAQ: JBL) is a double-narrative, and investors will like both. On the one hand, it’s suffering from end-market weakness, impacting the outlook for top-line growth. That has put some pressure on the market and caused the stock price to be corrected following the FQ4 release in... Read the Full Story |
|
Markets | |
Choosing where to stow away your hard-earned money can feel overwhelming at times.
Should you venture into the dynamic growth potential of an individual retirement account (IRA), park your money in the reliable corner of a certificate of deposit (CD) or perhaps find a middle ground with a money ... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Healthcare | |
Coming into prominence during the COVID-19 pandemic, telemedicine stocks saw increases in price and profitability in the past five years. As relaxed government regulations allowed service providers to offer an enhanced range of virtual assistance offerings, investors soon became interested in tele... Read the Full Story |
|
Markets | |
You've heard of dividend stocks and how they can provide a small income for holding them. They tend to be suitable for conservative investors, often retirees seeking an income stream from their investments. However, not all dividend stocks are conservative.
If you're willing to take on more risk... Read the Full Story |
|
Technology | |
Adobe’s (NASDAQ: ADBE) FQ4 results echoed Oracle’s (NASDAQ: ORCL), causing the shares to fall following the release. The primary cause for the decline is the guidance, which is favorable to shareholder value but slightly less than the analysts expected. The takeaway is that business re... Read the Full Story |
|
Finance | |
Your job as an investor is to make sure that you can buy wonderful businesses at fair prices, which is what Charlie Munger (rest his soul) taught Warren Buffett to get him to pivot from accepting what he referred to as 'cigar butts.' Today, the oracle of Omaha has found a few wonderful businesses ... Read the Full Story |
|
Technology | |
If you've been looking for smart investments to add to your portfolio, you may have come across the term "blue chip stocks." Blue chip stocks are renowned for being reliable investments and can offer investors numerous advantages.
This article will give you a comprehensive overview of the answer... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina. | | View Today's Stock Pick |
|
